Search results
Germany’s Merck Bets on AI Drug-Design Partnerships, Rules Out Acquisitions – Interview
The Wall Street Journal· 10 hours agoMerck—known as EMD Group in the U.S.— is betting on artificial-intelligence partnerships to develop...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 5 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
AstraZeneca PLC ADR TradeGate Stock Price Today | NASDAQ AZNPy Live Ticker - Investing.com
Investing.com· 2 days agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...
Lung cancer treatment produces progression-free survival results in Phase III trial
Medical Xpress· 2 days agoOsimertinib, produced by AstraZeneca under the brand name Tagrisso, significantly extends the time patients live without their cancer worsening, offering the first effective ...
Astra’s Enhertu delays breast cancer in patients with low HER2 levels
WSAU Wausau· 5 days agoBy Deena Beasley (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to...
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer
MedPage Today· 6 days agoThe antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved...
Women denied ‘wonder drug’ that could double terminal breast cancer life expectancy
Daily Telegraph· 4 days agoWomen with HER2-low or ultra-low breast cancer who took Enhertu lived without their cancer growing...
Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits
CNBC· 4 days agoCompany logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain...
SGLT2s With Diuretics Improve Heart Failure Outcomes
Medscape· 17 hours agoPatients with acute heart failure on the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin who received diuretic therapy experienced rapid...
Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Zacks via Yahoo Finance· 1 day agoEmpaveli recorded sales of $25.6 million in the reported quarter, up 25.5% from the year-ago...